Abstract
Aortic medial amyloid (AMA) occurs as localised non-atheromatous plaques in virtually all individuals over the age of 50. The major protein component of AMA is the 50-residue polypeptide medin. Here we propose two methods of manipulating medin aggregation to reduce the cytotoxic species of medin: either by promoting formation of larger benign species or retaining small non-cytotoxic species. Medin co-localises with a variety of factors including glycosaminoglycans (GAGs). The first approach shows that the GAG heparin enhances the rate of medin aggregation and alters the morphology of the amyloid fibrils. Cellular viability measurements suggest that heparin eliminates small cytotoxic species of medin, promoting formation of benign fibrils. The second approach applies a previously successful approach of designing small peptide moieties that are complementary to the key amyloidogenic sequence but which contain modified amino acids known to disrupt hydrogen bonding and therefore prevent aggregation of the target protein. This approach also reduces cellular toxicity of medin at all stages of the aggregation process examined exhibiting a different mode of action to heparin. These results raise the question of whether enhancement of medin aggregation by GAGs is beneficial, by eliminating toxic oligomers, or has deleterious effects by reducing arterial plasticity associated with increased fibril load and whether small peptide inhibitors can be applied as drug candidates for amyloid diseases.
Similar content being viewed by others
Abbreviations
- AMed42–49 :
-
Peptide corresponding to residues 42–49 of medin
- AMA:
-
Aortic medial amyloid
- BA:
-
β-Alanine
- DLS:
-
Dynamic light scattering
- GABA:
-
γ-Aminobutyric acid
- GAG:
-
Glycosaminoglycan
- HSPG:
-
Heparin sulphate proteoglycan
- MTT:
-
(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
- TEM:
-
Transmission electron microscopy
- ThT:
-
Thioflavin T
- SRE:
-
Self-recognition element
References
Alexandrescu AT (2005) Amyloid accomplices and enforcers. Protein Sci 14:1–12
Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S (2004) Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431:805–810
Bodner RA, Housman DE, Kazantsev AG (2006a) New directions for neurodegenerative disease therapy—using chemical compounds to boost the formation of mutant protein inclusions. Cell Cycle 5:1477–1480
Bodner RA, Outeiro TF, Altmann S, Maxwell MM, Cho SH, Hyman BT, McLean PJ, Young AB, Housman DE, Kazantsev AG (2006b) Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington’s and Parkinson’s diseases. Proc Natl Acad Sci USA 103:4246–4251
Bucciantini M, Giannoni E, Chiti F, Baroni F, Formigli L, Zurdo J, Taddei N, Ramponi G, Dobson CM, Stefani M (2002) Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416:507–511
Calamai M, Kumita JR, Mifsud J, Parrini C, Ramazzotti M, Ramponi G, Taddei N, Chiti F, Dobson CM (2006) Nature and significance of the interactions between amyloid fibrils and biological polyelectrolytes. Biochemistry 45:12806–12815
Cardin AD, Weintraub HJR (1989) Molecular modelling of protein-glycosaminoglycan interactions. Arteriosclerosis 9:21–32
Castillo GM, Cummings JA, Yang WH, Judge ME, Sheardown MJ, Rimvall K, Hansen JB, Snow AD (1998) Sulphate content and specific glycosaminoglycan backbone of perlecan are critical for perlecan’s enhancement of islet amyloid polypeptide (amylin) fibril formation. Diabetes 47:612–620
Chiti F, Dobson CM (2006) Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem 75:333–366
Cohlberg JA, Li J, Uversky VN, Fink AL (2002) Heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from α-synuclein in vitro. Biochemistry 41:1502–1511
Ehrnhoefer DE, Bieschke J, Boeddrich A, Herbst M, Masino L, Lurz R, Engemann S, Pastore A, Wanker EE (2008) EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol 15:558–566
Haggqvist B, Naslund J, Sletten K, Westermark GT, Mucchiano G, Tjernberg LO, Nordstedt C, Engstrom U, Westermark P (1999) Medin: an integral fragment of aortic smooth muscle cell-produced lactadherin forms the most common human amyloid. Proc Natl Acad Sci USA 96:8669–8674
Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300:486–489
Konno T, Oiki S, Morii T (2007) Synergistic action of polyanionic and non-polar cofactors in fibrillation of human islet amyloid polypeptide. FEBS Letters 581:1635–1638
Kvam E, Nannenga BL, Wang MS, Jia Z, Sierks MR, Messer A (2009) Conformational targeting of fibrillar polyglutamine proteins in live cells escalates aggregation and cytotoxicity. PLoS ONE 4:e5727
Larsson A, Soderberg L, Westermark GT, Sletten K, Engstrom U, Tjernberg LO, Naslund J, Westermark P (2007) Unwinding fibril formation of medin, the peptide of the most common form of human amyloid. Biochem Biophys Res Commun 361:822–828
Lashuel HA, Hartley D, Petre BM, Walz T, Lansbury PTJ (2002) Amyloid pores from pathogenic mutations. Nature 418:291
Levine H (1993) Thioflavin T interaction with synthetic Alzheimer’s disease β-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci 2:404–410
Madine J, Copland A, Serpell LC, Middleton DA (2009a) Cross-β spine architecture of fibrils formed by the amyloidogenic segment NFGSVQFV of medin from solid-state NMR and X-ray fiber diffraction measurements. Biochemistry 48:3089–3099
Madine J, Wang X, Brown DR, Middleton DA (2009b) Evaluation of beta-alanine- and GABA-substituted peptides as inhibitors of disease-linked protein aggregation. ChemBioChem 10:1982–1987
Masuda M, Suzuki N, Taniguchi S, Oikawa T, Nonaka T, Iwatsubo T, Hisanaga S-i, Goedert M, Hasegawa M (2006) Small molecule inhibitors of α-synuclein filament assembly. Biochemistry 45:6085–6094
Merlini G, Westermark P (2004) The systemic amyloidoses: clearer understanding of the molecular mechanisms offers hope for more effective therapies. J Intern Med 255:159–178
Olofsson A, Borowik T, Grobner G, Sauer-Eriksson AE (2007) Negatively charged phospholipid membranes induce amyloid formation of media via an alpha-helical intermediate. J Mol Biol 374:186–194
Peng SW, Westermark GT, Sletten K, Glennert J, Westermark P (2001) Distribution of medin-amyloid in aging and in association with arterial diseases. Amyloid 8:122–123
Peng S, Larsson A, Wassberg E, Gerwins P, Thelin S, Fu X, Westermark P (2007) Role of aggregated medin in the pathogenesis of thoracic aortic aneurysm and dissection. Lab Invest 87:1195–1205
Snow AD, Sekiguchi R, Nochlin D, Fraser P, Kimata K, Mizutani A, Arai M, Schreier WA, Morgan DG (1994) An important role of heparan sulfate proteoglycan (perlecan) in a model system for the deposition and persistence of fibrillar aβ-amyloid in rat brain. Neuron 12:219–234
van Horssen J, Wesseling P, van den Heuvel LPWJ, de Waal RMW, Verbeek MM (2003) Heparan sulphate proteoglycans in Alzheimer’s disease and amyloid-related disorders. Lancet Neurol 2:482–492
Watson DJ, Lander AD, Selkoe DJ (1997) Heparin-binding properties of the amyloidogenic peptides A beta and amylin—dependence on aggregation state and inhibition by Congo red. J Biol Chem 272:31617–31624
Acknowledgments
The Alzheimer’s Research Trust is acknowledged for a Fellowship to JM. DAM is supported by funding from the BBSRC and the British Heart Foundation.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Madine, J., Middleton, D.A. Comparison of aggregation enhancement and inhibition as strategies for reducing the cytotoxicity of the aortic amyloid polypeptide medin. Eur Biophys J 39, 1281–1288 (2010). https://doi.org/10.1007/s00249-010-0581-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00249-010-0581-3